Summary

Kymera Therapeutics is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop innovative medicines that address critical health problems. Founded in 2016 and headquartered in Watertown, Massachusetts, Kymera leverages its proprietary Pegasus platform to create oral small molecule degraders that target disease-causing proteins previously considered undruggable. The company focuses on developing treatments for immuno-inflammatory diseases, with its lead programs targeting STAT6 and IRAK4 proteins. Kymera has advanced the first degrader into clinical trials for immunological diseases and is working to provide a new generation of convenient, highly effective oral therapies. The company employs 51-200 people and has been recognized as one of Boston's top workplaces, demonstrating its commitment to both scientific innovation and employee culture. Kymera represents a transformative approach to drug development by harnessing the body's natural protein recycling machinery to degrade dysregulated proteins, offering potential breakthroughs for patients with conditions that lack effective treatment options.

Job description

How you'll make an impact

Drive Kymera's business development strategy, positioning our targeted protein degradation platform and pipeline at the center of strategic partnerships.
Identify, evaluate, and close strategic transactions with leading biopharma companies— spanning both buy- and sell-side opportunities.
Own transactions end to end, from initial opportunity through signature agreement, working closely with R&D, legal, finance, and outside counsel.
Lead and coordinate cross-functional diligence teams.
Prepare high-quality partnering materials, including presentations, term sheets, valuation models to support transaction processes.
Lead search and evaluation processes for prioritized external opportunities.
Develop financial analyses, including forecasts, comparables, and NPV valuations, to inform critical decisions.
Lead negotiation and execution of collaboration agreements (licensing and collaboration agreements, SRAs, MTAs, and CDAs) in close partnership with internal and external council.
Represent Kymera in the industry, building relationships with BD counterparts at current and potential partner companies
Represent Kymera at partnering conferences and industry events (eg. JPM, BIO) to build and maintain relationships with potential partners and support S&E activity.

Skills and experience you'll bring

An advanced degree — PhD, MD, or MBA — that reflects both scientific fluency and business acumen.
8+ years of experience in business development, corporate development, or strategy consulting in biopharma.
Experience across the full deal lifecycle: sourcing, diligence, negotiation, and structuring.
Demonstrated success working with cross-functional teams and managing multiple concurrent projects
Strong strategic judgment, the ability to work independently and represent Kymera externally
NPV modeling, forecasting, and comparables analysis with the ability to communicate results clearly.
A track record of evaluating opportunities from both a scientific and commercial perspective.
Working knowledge of biopharma R&D (experience with small molecules is a plus), clinical development, and regulatory pathways
Excellent negotiation, written, and presentation skills.

Requirements

An advanced degree — PhD, MD, or MBA — that reflects both scientific fluency and business acumen.
8+ years of experience in business development, corporate development, or strategy consulting in biopharma.
Experience across the full deal lifecycle: sourcing, diligence, negotiation, and structuring.
Demonstrated success working with cross-functional teams and managing multiple concurrent projects
Strong strategic judgment, the ability to work independently and represent Kymera externally
NPV modeling, forecasting, and comparables analysis with the ability to communicate results clearly.
A track record of evaluating opportunities from both a scientific and commercial perspective.
Working knowledge of biopharma R&D (experience with small molecules is a plus), clinical development, and regulatory pathways
Excellent negotiation, written, and presentation skills.

Benefits

Annual bonus
Equity participation
Comprehensive benefits

Company overview

Kymera Therapeutics is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop innovative medicines that address critical health problems. Founded in 2016 and headquartered in Watertown, Massachusetts, Kymera leverages its proprietary Pegasus platform to create oral small molecule degraders that target disease-causing proteins previously considered undruggable. The company focuses on developing treatments for immuno-inflammatory diseases, with its lead programs targeting STAT6 and IRAK4 proteins. Kymera has advanced the first degrader into clinical trials for immunological diseases and is working to provide a new generation of convenient, highly effective oral therapies. The company employs 51-200 people and has been recognized as one of Boston's top workplaces, demonstrating its commitment to both scientific innovation and employee culture. Kymera represents a transformative approach to drug development by harnessing the body's natural protein recycling machinery to degrade dysregulated proteins, offering potential breakthroughs for patients with conditions that lack effective treatment options.